Daiichi Sankyo Presents Triple Combo Hypertension Results, Aims For No. 1 Combo Market Share

Daiichi Sankyo May 8 announced results of a Phase III study showing that triple combination therapy of olmesartan, amlodipine and hydrochlorothiazide demonstrated significantly greater mean reduction in blood pressure compared to corresponding double combo therapy